SNDX Syndax Pharmaceuticals, Inc.
Healthcare$19.90-0.20%ClosedMarket Cap: $1.76B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
41.50
P/S
8.14
EV/EBITDA
-12.19
DCF Value
$14.13
FCF Yield
-15.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
98.0%
Operating Margin
-102.9%
Net Margin
-112.0%
ROE
-256.7%
ROA
-51.5%
ROIC
-57.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $64.9M | 95.9% | $-34.2M | $-42.7M | $— | — |
| Q4 null | $68.5M | 102.3% | $-62.5M | $-68.0M | $— | — |
| FY null | $172.4M | 96.0% | $-273.1M | $-285.4M | $— | — |
| Q3 null | $45.9M | 95.4% | $-57.4M | $-60.7M | $— | — |
| Q2 null | $38.0M | 96.6% | $-69.4M | $-71.8M | $— | — |
| Q1 null | $20.0M | 95.6% | $-83.8M | $-84.8M | $— | — |
| Q4 null | $7.7M | 100.0% | $-96.4M | $-94.2M | $— | — |
| FY null | $23.7M | 96.5% | $-339.7M | $-318.8M | $— | — |
| Q3 null | $12.5M | 100.0% | $-89.6M | $-84.1M | $— | — |
| Q2 null | $3.5M | 100.0% | $-74.2M | $-68.1M | $— | — |
| Q1 null | $0.00 | NaN% | $-79.5M | $-72.4M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-77.9M | $-72.5M | $-1.00 | — |